Crinetics Pharmaceuticals (CRNX) Cash & Current Investments (2017 - 2026)

Crinetics Pharmaceuticals' Cash & Current Investments history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 1.35% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 1.35% increase from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 24.09% from the prior year.
• Cash & Current Investments grew to $1.3 billion in Q1 2026 per CRNX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.4 billion in Q4 2024 and bottomed at $54.2 million in Q2 2025.
• The 5-year median for Cash & Current Investments is $554.7 million (2023), against an average of $637.9 million.
• Across the five-year window, Cash & Current Investments jumped 226.22% in 2024 and sank 93.72% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $334.4 million in 2022, then surged by 67.02% to $558.6 million in 2023, then surged by 142.42% to $1.4 billion in 2024, then slipped by 24.09% to $1.0 billion in 2025, then gained by 25.63% to $1.3 billion in 2026.
• Per Business Quant, the three latest CRNX Cash & Current Investments figures stand at $1.3 billion (Q1 2026), $1.0 billion (Q4 2025), and $111.4 million (Q3 2025).